ArticleACS biomaterials science & engineering2025
Biomolecule Conjugation Strategy for HAGM Cryogels to Create 3D Immune Niches that Induce Multifunctional T Cells.
Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, biomaterials have emerged as tools to activate and expand T cells in the context of cancer immunotherapy. Most designs accommodate T cells with a stimulatory two-dimensional (2D) environment. In contrast, three-dimensional (3D) scaffolds, mimicking the complex architecture of the lymph node, have been shown to outperform 2D synthetic constructs, resulting in a more optimal T-cell expansion and phenotype. Here, we used injectable glycidyl methacrylated hyaluronic acid (HAGM)-based cryogel scaffolds to create a modular biodegradable 3D stimulatory immune niche. We developed a strategy to achieve highly specific and efficient covalent linking of immune-activating biomolecules, such as T-cell-activating peptide MHC complexes and antibodies, to HAGM scaffolds without compromising the injectable properties of the cryogels. Importantly, because our conjugation strategy is carried out postcryogelation, biomolecules are not exposed to free radicals and freeze-thawing cycles, facilitating highly reproducible covalent attachment. Our scaffold potently activates human- and murine-T cells, inducing higher levels of multifunctional T cells with a less exhausted phenotype compared to 2D cultures. Following injections, HAGM scaffolds retain up to 60% of highly proliferative T cells. In conclusion, our HAGM scaffolds are an easily adaptable tool for robust T-cell activation, thus further expanding the biomaterial-based immunotherapy toolbox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.